Asset Details
Do you wish to reserve the book?
TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement
Do you wish to request the book?
TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement
2024
Overview
Severe tricuspid regurgitation remains largely undertreated given limited treatment options. Transcatheter tricuspid valve interventions have emerged as a promising therapy for these patients, and the TRISCEND II pivotal trial is the first randomized controlled trial to evaluate transcatheter tricuspid valve replacement (TTVR).
The TRISCEND II pivotal trial studies the transcatheter EVOQUE (Edwards Lifesciences, Irvine, California) tricuspid valve replacement system using a United States Food and Drug Administration Breakthrough Device Designation—a program intended to provide timely access to medical devices by speeding up development, assessment, and review.
The TRISCEND II trial is a prospective, multicenter trial that randomizes patients with symptomatic severe tricuspid regurgitation to treatment with either TTVR in conjunction with optimal medical therapy or optimal medical therapy alone. The trial's novel 2-phase design evaluates 30-day safety and 6-month effectiveness end points for the first 150 patients in the initial phase and a 1-year safety and effectiveness end point for the full cohort of 400 patients in the second phase.
The TRISCEND II trial's 2-phase trial design provided an opportunity for early review and led to the first commercial approval of a TTVR system.
In conclusion, the design of the TRISCEND II trial will likely inform future transcatheter tricuspid device trials.
Publisher
Elsevier Inc,Elsevier Limited
Subject
breakthrough device designation
/ Cardiac Catheterization - methods
/ EVOQUE
/ Heart Valve Prosthesis Implantation - methods
/ Humans
/ Multicenter Studies as Topic
/ Patients
/ Randomized Controlled Trials as Topic
/ Surgery
/ Therapy
/ transcatheter tricuspid valve replacement
